THJ-2201 is an indazole-based synthetic cannabinoid that presumably acts as a potent agonist of the CB1 receptor and has been sold online as a designer drug.
It is a structural analog of AM-2201 in which the central indole ring has been replaced by indazole.
THJ-2201 acts as a full agonist with a binding affinity of 1.34nM at CB1 and 1.32nM at CB2 cannabinoid receptors.
THJ-2201 has been linked to at least one hospitalization and death due to its use.
Because of the hazards associated with recreational use of this compound, it is classified as a Schedule I controlled substance in the United States.
It is also an Anlage II controlled drug in Germany.